LGL Group (NYSEAMERICAN:LGL) Share Price Crosses Above 200 Day Moving Average – Here’s Why

LGL Group, Inc. (The) (NYSEAMERICAN:LGL)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $6.54 and traded as high as $7.46. LGL Group shares last traded at $7.40, with a volume of 3,715 shares trading hands.

LGL Group Trading Down 2.2%

The firm has a market capitalization of $48.40 million, a P/E ratio of 67.27 and a beta of 0.34. The business’s 50 day simple moving average is $7.16 and its two-hundred day simple moving average is $6.54.

LGL Group (NYSEAMERICAN:LGL) last announced its quarterly earnings results on Monday, March 30th. The industrial products company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.09). The company had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $9.10 million. LGL Group had a net margin of 16.50% and a return on equity of 1.62%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in LGL Group stock. Osaic Holdings Inc. raised its position in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) by 15.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,250 shares of the industrial products company’s stock after purchasing an additional 2,710 shares during the quarter. Osaic Holdings Inc. owned 0.38% of LGL Group worth $154,000 as of its most recent SEC filing. Institutional investors own 30.28% of the company’s stock.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.